Abstract #4125

Redox Dysregulations in Schizophrenia Revealed by in vivo NAD+/NADH Measurement

Sang-Young Kim^1,2, Bruce Cohen³, Scott Lukas⁴, Cagri Yuksel², Dost Ongur², and Fei Du^1,2

¹McLean Imaging Center, McLean Hospital, Harvard Medical School, Belmont, MA, United States, ²Psychotic Disorders Division, McLean Hospital, Harvard Medical School, Belmont, MA, United States, ³Program for Neuropsychiatric Research, McLean Hospital, Harvard Medical School, Belmont, MA, United States, ⁴Behavioral Psychopharmacology Research Laboratory, McLean Hospital, Harvard Medical School, Belmont, MA, United States

In this work, we demonstrated the feasibility of 31P MRS-based in vivo intracellular redox state quantification at 4 T. We applied this novel method to investigate oxidative stress in the frontal lobe of chronic and first-episode SZ as well as first-episode BD patients. We found evidence for striking Rx reductions in SZ, with every chronic SZ patient showing an Rx of at least one standard deviation below the control mean. Rx reduction was of even greater magnitude among first-episode SZ patients. This study illustrates the power of examining in vivo brain redox dysregulation (measured as Rx) in psychiatric disorders.

This abstract and the presentation materials are available to members only; a login is required.

Join Here